A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients
Overview
- Phase
- Phase 4
- Intervention
- Anidulafungin
- Conditions
- Candidemia
- Sponsor
- Universidade Federal do Rio de Janeiro
- Enrollment
- 85
- Locations
- 1
- Primary Endpoint
- Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This is a prospective study aimed at testing a strategy of early initiation of an antifungal agent to patients admitted to intensive care units (ICUs) at risk for invasive candidiasis. Score system have been developed to identify groups at very high risk for the development of candidemia/invasive candidiasis in the ICU. These scoring system have used clinical information with or without data on Candida colonization, and have shown reasonable correlation with candidemia/invasive candidiasis. More recently, a biomarker - detection of 1,3-beta-D-glucan in the serum - has been tested in the early diagnosis of candidiasis. The incorporation of biomarkers such as beta-D-glucan could help clinicians to select a group at higher risk for candidemia, and despite the fact that these tests may give false-positive results, their negative predictive value could be of great help.
Therefore, the objectives of this study are:
- To assess the frequency of positive biomarkers in ICU patients at high risk to develop invasive candidiasis/candidemia;
- To test the strategy of early discontinuation of antifungal therapy based on repeatedly negative blood cultures and 1,3 beta-D-glucan in the serum.
Detailed Description
Entry criteria are: In the ICU for \>2 days AND systemic antibiotics \>2 days OR central venous catheter for \>days AND at least two of the following: total parenteral nutrition, dialysis, surgery, pancreatitis, receipt of corticosteroids, receipt of other immunosuppressive agents. In addition, patients must have a clinical sign of infection (either one of the following): fever, hypothermia, hypotension, unexplained acidosis, or unexplained elevation in C-reactive protein. Eligible patients will be enrolled after signing an informed consent and will have blood obtained for culture and determination of 1,3 beta-D-glucan serum levels for 3 days, and will start anidulafungin IV. If all tests are negative, anidulafungin will be discontinued on day 4. If 1,3 beta-D-glucan is positive (\>80 pg/ml) and / or blood cultures are positive for Candida species, anidulafungin will be continued for \>14 days.
Investigators
Marcio Nucci
MD
Universidade Federal do Rio de Janeiro
Eligibility Criteria
Inclusion Criteria
- •In the ICU for \>2 days AND
- •Systemic antibiotics on days 1-3 of ICU OR
- •Central venous catheter on days 1-3 of ICU
- •AND at least 2 of:
- •Total parenteral nutrition on days 1-3 of ICU
- •Any dialysis on days 1-3 of ICU
- •Major surgery in the 7 days before admission in the ICU
- •Pancreatitis in the 7 days before admission in the ICU
- •Use of corticosteroids for at least 3 days in the 7 days before admission
- •Use of other immunosuppressive agents in the 7 days before admission in the ICU
Exclusion Criteria
- •Antifungal for \>3 days
- •Allergy to an echinocandin
Arms & Interventions
Anidulafungin
Patients at risk will receive therapy with anidulafungin
Intervention: Anidulafungin
Outcomes
Primary Outcomes
Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin
Time Frame: 30 days
The main interest is to evaluate the ocurrence of candidemia in patients with negative 1,3 beta-D-glucan who discontinue anidulafungin